Approval of medicines relies on the evaluation of their risk-benefit profile. Price and reimbursement negotiation requires a step forward, since payers are interested in comparative (relative) assessment and economic evaluation of medicines. This course provides an overview of the domains of comparative assessment (health technology assessment) with a specific focus on economic evaluations (cost-effectiveness and budget impact analysis). Examples of cost-effectiveness studies will be critically discussed using the CHEERS evaluation form.
AULA ...................
- Docente: JommiClaudio